Condition: Advanced Cancers · Sponsor: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
This is a Phase I clinical study aimed at evaluating the safety and pharmacokinetics of TQB2922 subcutaneous injection in patients with advanced cancers.
This description comes directly from the study's public registry record.
Li Zhang, Doctor · 020-87343458 · zhangli@sysucc.org.cn
Always discuss trial participation with your own doctor first.
| Sun Yat-sen University Cancer Center | Guangzhou, Guangdong, China | Recruiting |
| Henan Cancer Hospital | Zhengzhou, Henan, China | Recruiting |
| The First Affiliated Hospital of Zhengzhou University | Zhengzhou, Henan, China | Not Yet Recruiting |
| Hunan Cancer Hospital | Changsha, Hunan, China | Not Yet Recruiting |
| Nanjing Drum Tower Hospital | Nanjing, Jiangsu, China | Recruiting |
| The First Affiliated Hospital of Nanchang University | Nanchang, Jiangxi, China | Recruiting |
| Affiliated Zhongshan Hospital of Dalian University | Dalian, Liaoning, China | Recruiting |
| Shandong Cancer Hospital | Jinan, Shandong, China | Recruiting |
| Shanghai Pulmonary Hospital | Shanghai, Shanghai Municipality, China | Recruiting |
| West China hospital, Sichuan University | Chengdu, Sichuan, China | Not Yet Recruiting |
| Chengdu Third People's Hospital | Chengdu, Sichuan, China | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07260708